Podcasts about vanguards

Sure, we've reviewed the fastest World Tour aero road bikes and the newest gravel machines, but what about an off-road capable folding bike? Variety is the spice of life, and Velo tech editor Alvin Holbrook has been getting spicy on Brompton's G Line, a bike that should be more capable than any of the legendary UK brand's previous offerings, thanks to larger wheels and much better tires and brakes. Alvin rode the G Line on his usual gravel test loop and reports back on how it performed and what type of rider it makes the most sense for. Would you wear AI on your face? Josh Ross has been in the shape of Oakley's new – and very expensive – Vanguard glasses that come with a video camera, mic and headphones, and a connection to artificial intelligence that's ready to answer *almost* any question you might have. Josh answers our questions, without any AI help, about what the Vanguards are like to live with, why they might have the best mic and headphones for cycling, and explains how they can actually cost less than buying separate glasses, headphones, and a camera. Levy has that new bike fizz after buying an Allied Able and shares some of his early ride impressions, as well as how it compares to his much-loved Santa Cruz Stigmata that he's lived on for the previous two years. Is it love at first ride, or might there be some regrets? Further reading Q36.5's New Cold-Weather Jackets Fit Like A … Condom? How Strava Traded User Goodwill for Nothing Mathieu van der Poel Spotted on an Unreleased Canyon Prototype Road Bike. Here's What We Know. Vittoria's New Gravel Tire is Faster AND Better for the Environment | This Week in Bike Tech Can a Folding Bike Actually Handle Gravel? We Pushed the Brompton G Line to the Limit. Garmin Teamed Up With Oakley and Meta to Make Smart Glasses We Actually Want to Wear 0:00 Intro2:02 Alvin and Josh: Are the Meta x Oakley glasses good for cycling?30:00 Brompton G-Line41:20 Are the new Vittoria gravel tires greenwashing?46:35 Levy's new bike day!1:08:20 We want your input on a new Zwift ride!

“What you have to do in a market like that, where it’s highly genericized, is first you have to have a clinical differentiation,” says Richard Lowenthal, CEO of ARS Pharmaceuticals. “You have to have a benefit to the community, benefit to the patient population. Neffy achieves that very effectively by providing an option that’s very simple — it’s easy to carry, it’s very easy to use.” In this episode of Vanguards of Health Care, Richard sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the company has navigated the commercial launch of its needle-free epinephrine nasal spray, neffy, in a highly competitive genericized market.See omnystudio.com/listener for privacy information.

“In a world where we have so many wearables — smart rings, watches, glucose sensors — it’s challenging to integrate all of this information,” say Biolinq founder Jared Tangney and CEO Rich Yang. “So we decided to make it available to everybody in one device.” In this Vanguards of Health Care episode, the pair speak with Bloomberg Intelligence’s analyst Matt Henriksson about Biolinq’s microsensor-based patch that uses silicon semiconductor technology to track glucose and potentially other biomarkers. They also discuss the company’s commercial strategy for type 2 diabetes patients following its FDA de Novo approval, a US regulatory designation granted to first-of-its-kind medical devices that have been shown to be safe and effective.See omnystudio.com/listener for privacy information.

A whole bunch of new tracks to check out, loads of albums dropping these days. Jabs is back on deck with Oaks. Playlist: What Drives You by The Profit Menorah by Jackie Hill Perry & nobigdyl. Fair Warning by J.Solo ft. Knaladeus Keep Me First by Brinson ft. Dre Murray Power Moves by Vanguards, Mic Wise & Trutha ft. GB & Bill B. Vengeance II by Tae Lamar ft. MotionPlus, Propaganda & m1L HARD OUT HERE! by DJ Mykael V & Gavin the HotRod ft. Aable UNDER THE BLOOD by Basecamp (Procyse & Rich Colon) ft. Knaladeus Breathe In by Yasad One Close Call by m1L & iNTELLECT As The World Turns by Q-Flo & IAMOPB Glorious by Still Shadey Marz Barz III by R.kitect Boyz II Men by Jered Sanders Vote on the playlist at www.definitionradio.com/show/972 Leave your requests/shout-outs on our socials www.facebook.com/DefinitionRadio www.instagram.com/DefinitionHH www.twitter.com/DefinitionHH www.krosswerdz.com

“The same was in neuro intervention for aneurysms, it was open clipping or it was endovascular. And I think that’s what’s happening in BCI. So there’s a bunch of craniotomy-based, open BCI companies, and then there’s an interventional approach”, Synchron’s founder and CEO Tom Oxley explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Tom sits down with BI analyst Matt Henriksson for an in-depth interview about the company and how he utilized his experience with minimally invasive endovascular procedures to create its Stentrode as novel way to utilize brain-computer interfaces (BCI) without open brain surgery.See omnystudio.com/listener for privacy information.

“It’s hard to overemphasize how broken we are in how we care for older adults.” says Seth Sternberg, CEO of Honor. Sternberg joins Bloomberg Intelligence analyst Jonathan Palmer to unpack how Honor’s AI-driven logistics and the Home Instead network tackle the hardest problem in home care: scaling quality. In this episode of the Vanguards of Health Care podcast they dive into matching the right caregiver to the right client, why stability is the No. 1 caregiver need, franchise advantages, and making private‑pay care more affordable for the middle class plus how quality metrics and “defect rates” power growth.See omnystudio.com/listener for privacy information.

“When we talk about spine, having 7D, which is a highly differentiable product for deformities, I think it’s giving us the basis to become a real player and help to solve the most complex issues into spine,” Orthofix’s CEO Massimo Calafiore says as he explains the future of spine navigation. In this Vanguards of Health Care episode, Calafiore sits down with Bloomberg Intelligence analyst Matt Henriksson for an in-depth interview about the benefits of its 7D navigation in spine procedures that utilizes camera-based technology combined with machine-vision algorithms, the growth opportunities in specialized orthopedics, including limb preservation and extremity deformity correction, and how he built a new management team from the ground up to tackle these opportunities. See omnystudio.com/listener for privacy information.

“We thought that the folks would only turn on stimulation when they felt faint or lightheaded, but in fact, they’re using the stimulation the entire waking day because the stimulation is stabilizing their blood pressure, more oxygenation is reaching their brain,” Onward Medical CEO Dave Marver explains in this Vanguards of Health Care podcast episode. Marver sits down with Bloomberg Intelligence analyst Matt Henriksson for an in-depth interview about Onward and how its developments differ from other companies that utilize brain-computer interfaces (BCI) by connecting BCI technology to its ARC platform to stabilize blood pressure and restore movement of the human body, instead of simply using the patient’s thoughts to control computer functions. Marver also discusses the initiation of its Empower BP Pivotal study to assess the use of its ARC-IM system to address blood-pressure instability after spinal cord injuries (SCI).See omnystudio.com/listener for privacy information.

“Doctors don’t want pharma reps to buy them dinner, right? They don’t. They want help in the five minutes that really matter,” Viz.ai’s CEO Chris Mansi and Salesforce’s Frank Defesche explain in this Vanguards of Health Care podcast episode. Mansi and Defesche sit down with Bloomberg Intelligence analyst Matt Henriksson to talk about Viz.ai and its agentic AI platform that connects medical scans and images to the right diagnosis and treatment guidelines. Also tune in to learn how the Viz.ai platform aims to partner with Salesforce’s life-science division to improve pharmaceutical point-of-care workflow while providing more personalized care.See omnystudio.com/listener for privacy information.

“Our vision as a company is to help eradicate cancer with tests that prevent it, detect it earlier and guide treatment,” says Kevin Conroy, CEO of Exact Sciences. He joins Bloomberg Intelligence analyst Jonathan Palmer on the Vanguards of Health Care podcast to trace Exact’s journey into a cancer-diagnostics leader. From Cologuard’s initial rise to its recently launched Cologuard Plus test, the debut of Cancerguard and expansion into minimal-residual disease (MRD) testing, Conroy shares how science, technology and culture underpin the company’s next decade.See omnystudio.com/listener for privacy information.

The Galaxy is no longer suffering from flickering shadows, judging by early observations. And an updated version of Squadrons has been released, bringing Squadron Carriers and the ability to transfer credits directly to other Commanders in the same Squadron.

The "Vanguards" change to Squadron organisation is coming in less than a week. Meanwhile, Community Goal records are tumbling, with additional Rail Guns rewards unlocked.

“We've been working with NVIDIA for a number of years now and we integrated a medical grade, GPU in our commercial product”, CEO Anne Osdoit explains to Bloomberg Intelligence in her description about how AI is being incorporated into Moon Surgical’s surgical robot. In this Vanguards of Health Care podcast episode, Osdoit sits down with BI analyst Matt Henriksson for an in-depth interview on Moon Surgical, the benefits of its Maestro AI-powered surgical platform, and how Maestro can address the current barriers that have kept penetration rates of robotic surgery low.See omnystudio.com/listener for privacy information.

“American medicine is the best in the world, but the American health-care system is not,” Akasa CEO Malinka Walaliyadde says. In this Vanguards of Health Care episode, Walaliyadde joins Bloomberg Intelligence analyst Jonathan Palmer to explore how Akasa is tackling the chaos of revenue-cycle management with AI. He explains why America’s overlapping payment models create inefficiency, how large-language models read massive patient records in minutes and why custom models built for each health system outperform off-the-shelf AI. They also discuss Akasa’s performance-based business model and the path toward real-time payer-provider communication, as well as the role that grit and conviction play in building a transformative company.See omnystudio.com/listener for privacy information.

We finally have time to talk about the Vanguards update, and have many thoughts about a very content heavy week!Elite Dangerous Vanguards Patch 2 – https://forums.frontier.co.uk/threads/elite-dangerous-vanguards-patch-2.640923/Mystery to be unlocked – https://canonn.science/codex/a-secret-to-be-uncovered-a-trail-to-be-followed/Community NewsFan made colonisation map – https://oasis-cartograph.onrender.com/Alec's colonisation systems forum thread – https://forums.frontier.co.uk/threads/alecs-guide-to-interesting-colonisation-systems-and-stations.638893/#post-10659743

The worst thing that can happen in health-care and biomedical research is politics getting involved in choosing what research needs to be done for what disease, Dr. Elias Zerhouni tells Bloomberg Intelligence analyst Sam Fazeli, explaining how mixing science and politics weakens innovation and public trust. On this episode of the Vanguards of Health Care podcast, Zerhouni, a former NIH director and vice chairman of OPKO Health, unpacks his new book Disease Knows No Politics, warns against cutting US research funding and explains why immigration is vital for scientific leadership. He also dives into OPKO and ModeX’s cutting-edge work on multivalent vaccines and multi-specific antibodies that could change the treatment landscape. See omnystudio.com/listener for privacy information.

“We are reinventing ourselves. We don’t want to be just a legacy orthopedic company and I think we’re driving with the same enthusiasm as Arnold Schwarzenegger,” Zimmer Biomet Chairman, President and CEO Ivan Tornos tells Bloomberg Intelligence. In this Vanguards of Health Care episode, Tornos sits down with BI analyst Matt Henriksson for an in-depth interview about Zimmer Biomet and the strategic initiatives made through internal developments and key acquisitions, including Paragon 28 and Monogram, to accelerate its weighted average market growth rate (WAMGR). He also discusses the current orthopedic landscape and the opportunities arising from the shift to the ambulatory surgical center (ASC) setting, as well as his relationship with Arnold Schwarzenegger as Chief Movement Officer.See omnystudio.com/listener for privacy information.

“If you can drive the brain’s naturally occurring activity, what you can get is the biologic expression that is important for brains to maintain and protect themselves,” Cognito Therapeutics’ CEO Christian Howell tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Howell sits down with BI analyst Matt Henriksson to discuss the company and its Spectris device — a non-invasive therapeutic intervention designed to use gamma waves to preserve brain structure and function, starting with Alzheimer’s patients. He also highlights the promise of Cognito’s Hope study and reflects on how his time in the Navy and at Medtronic under former CEO Omar Ishrak shaped his “fidelity to the mission” leadership mantra.See omnystudio.com/listener for privacy information.

The crew discuss the latest update, Vanguards and Shadows, and reflect on a fantastic ECM. Community News:“Ludicrous! The Drakhyr Rally” by Cmdr Homborger -https://edrushfleet.co.uk/2025/08/19/ludicrous-the-drakhyr-rally/“A Valley of Ice and Sand” (Out There) by Commander Exorcist - https://youtu.be/u9kS-xiYcoU“Elite Dangerous: Odyssey - Exploration Montage | Episode 19” by coeneman02 - https://youtu.be/d4k-440dchk“Doing this made Elite Dangerous So much better !” by Erad*Prime - https://youtu.be/ufPO-FLR-X8“SPECIAL Elite Dangerous: Corsair Mass Meet Up” by The Buur Pit - https://youtu.be/4lRd6mTZj0Ehttps://edastro.com/galmap/#-366,0,436,6Alec's annotated map: https://i.imgur.com/6LjTfoj.png Download the episode directly from here

The crew fight latency issues and discuss their favourite of the last six ships introduced to the game.

“Saturday Mornings Show” host Glenn van Zutphen and co-host Neil Humphreys speak to Zat Astha, Editor-in-Chief of The Peak Magazine about the “Peak Power List 2025” and who made the cut this year under the theme of “Vanguards.”See omnystudio.com/listener for privacy information.

“When a patient comes in for a routine outpatient echo, we’ll be able to help with diagnosis and reduce the misdiagnosis at that point, number one,” Ultromics’ Founder and CEO Ross Upton explains to Bloomberg Intelligence analyst Matt Henriksson about the initial benefits of EchoGo for heart failure and cardiac amyloidosis. In this episode of the Vanguards of Health Care podcast, Upton also delves into the future of diagnosing and treating heart failure with artificial intelligence, saying it can additionally “really accurately phenotype them, and so the clinician would understand after the echo is done what treatments or what next diagnostic tests the patient needs, and they would understand it there and then without having to go through and try and figure out the pieces of the puzzle.” Also tune in to learn how Ultromics plans to use to recently announced Series C financing as it commercializes EchoGo for heart failure and cardiac amyloidosis.See omnystudio.com/listener for privacy information.

“I like the label ‘new operating system.’ I think that does capture well what we're trying to do here,” says Dr. Ryan Schoenfeld, CEO of the Mark Foundation. In this episode of Vanguards of Health Care, Schoenfeld joins Bloomberg Intelligence analyst Sam Fazeli to explore how the foundation is redesigning cancer research through global collaboration, platform thinking and a bold portfolio approach. They discuss the Foundation’s growing international footprint, why basic research is increasingly under threat in the US, and where new breakthroughs — including solid tumor CAR-T and glioblastoma — may emerge in the next five years.See omnystudio.com/listener for privacy information.

The bulk of today's show is spent talking about the Panther Clipper, how does it measure up to expectations? Our bumper sized crew have thoughts!

“We don’t have to do every great deal, but every deal we do has to be great,” says Payal Agrawal Divakaran, partner at .406 Ventures. In this Vanguards of Health Care episode, she joins Bloomberg Intelligence analyst Jonathan Palmer to unpack how .406 backs early-stage startups at the intersection of health care, tech and AI. They dive into the firm’s thesis-driven investing, why care delivery must be reimagined for complex populations and what Epic’s priorities mean for hospital-facing AI startups. Plus, the origins of the firm’s baseball-inspired name and why being mission-driven is non-negotiable for its founders.See omnystudio.com/listener for privacy information.

This week's headline reads like a financial horror story — and unfortunately, it's a true one.

The crew discuss the upcoming Vanguards update and catch up on the last two weeks after an amazing interview with Arthur!

“The PBM space has been worse than some criminal enterprises — they are stealing money from employers and employees,” says Jordan Feldman, CEO and co-founder of Rightway Healthcare. Feldman joins Bloomberg Intelligence analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast to unpack how Rightway is building a member-first pharmacy benefit manager (PBM) — one without rebates, gimmicks or hidden margins. They dive into Rightway’s origin story, how its care-navigation platform grew to 3.5 million members, and why a transparent, clinically-grounded PBM is the antidote for industry dysfunction. Feldman also shares thoughts on GLP-1 drugs, AI and what it means to be the so-called N-of-one alternative to the Big 3 PBM’s monopoly.See omnystudio.com/listener for privacy information.

“We started Cleerly with the intent to make a comprehensive care pathway for evaluation, education, treatment and tracking for heart disease,” said Dr. Jim Min, the company’s founder and CEO. In this Vanguards of Health Care episode, Min sits down with BI analyst Matt Henriksson to discuss Cleerly and its comprehensive management platform that uses AI algorithms to boost the accuracy of interpreting CT scans, avoid false positives and make the diagnosis stage of treating the disease more efficient for doctors and hospitals. They also cover the need to drive the iterative process of clinical studies, including the TRANSFORM randomized trial for screening asymptomatic individuals with the aim of preventing sudden cardiac death.See omnystudio.com/listener for privacy information.

The crew discuss the upcoming Vanguards update and catch up on the last two weeks after an amazing interview with Arthur!

OvertureTi is designed in a way that allows you step by step to avoid a total knee [replacement] because it’s so bone-sparing,” Overture Orthopaedics cofounder Riley Williams tells Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Williams and CEO James Kim sit down with BI analyst Matt Henriksson to talk about Overture, the development of focalplasty and its benefits over total knee replacement as a minimally invasive treatment option. They also discuss the importance of treating osteoarthritis early in the disease progression. Additionally, tune in to learn how it was once cheaper for Kim to hand-deliver the implants and tools instead of using overnight delivery, and about Dr. Williams’ time as a consultant for Bill Hader’s character in the movie Trainwreck.See omnystudio.com/listener for privacy information.

“If you can image it, if you can light it up, then you know where it’s going to go,” Lantheus’ CEO Brian Markison says as he explains the future of imaging agents to Bloomberg Intelligence. “You know it’s going to get to the tumor, and then if you can attach basically a warhead to it, then you can deliver targeted radiation to that tumor.” In this episode of the Vanguards of Health Care podcast, Markison sits down with Bloomberg Intelligence analyst Matt Henriksson for an in-depth interview to discuss how the Pylarify and Definity imaging agents enhance disease detection compared with traditional imaging platforms. They also dive into the importance of manufacturing and logistics to get the agents to the right hospital at the right time and the future pipeline with a portfolio of agents under development to detect Alzheimer’s and neuroendocrine tumors.See omnystudio.com/listener for privacy information.

The crew look to the next Frontier Unlocked and speculate what will be revealed as part of the Vanguards update

“This isn’t just an incremental shift, it’s a drastically different treatment dynamic,” says Rob Barrow, CEO of MindMed. On this episode of Vanguards of Health Care, Barrow speaks with Bloomberg Intelligence analyst Jean Rivera Irizarry about how MM120, a pharmaceutically optimized form of LSD, could transform the treatment landscape for anxiety and depression. They explore MindMed’s unique no-therapy approach to psychedelic trials, the design of its pivotal Phase 3 studies, and how it’s navigating regulatory hurdles to bring this once-taboo drug class into the mainstream.See omnystudio.com/listener for privacy information.

"The idea is you could use AI and technology to help understand this data such that we can quantify it much more so, so that it can lead to much more objective decisioning rather than subjective decisioning,” Founder and CEO Wardah Inam explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Inam sits down with BI analyst Matt Henriksson for an in-depth interview to talk about Overjet, how its AI platform can analyze digital imaging that are already in the markets to make an tangible dental decision, and how Review Pass can connect directly with the insurers to reduce the coverage decision process from weeks to minutes.See omnystudio.com/listener for privacy information.

“Ease of use is what drives adoption,” Tandem Diabetes CEO John Sheridan explains to Bloomberg Intelligence about what can fuel further insulin-pump penetration. In this episode of Vanguards of Health Care, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview about Tandem’s Mobi pump, designed for discretion and simplicity, and the AI-powered Control-IQ Plus algorithm, now approved for both type 1 and type 2 diabetes. The conversation also touches on the company’s international market strategy, value-based reimbursement and future product development, including the tubeless Sigi.See omnystudio.com/listener for privacy information.

“We didn’t start Model to launch a company — we started it because no one else met our standards,” says Dr. Daniel Haders II, CEO and founder of Model Medicines. On this episode of Vanguards of Health Care, Haders speaks with Bloomberg Intelligence analyst Andrew Galler about building an AI-native drug discovery engine capable of identifying cryptic binding pockets and designing first-in-class drugs. They unpack why hit rates and novelty must go hand-in-hand, an overview of the company’s pan-antiviral MDL-001, and why generalizability — not reinforcement learning — is the true litmus test for AI in biotech.See omnystudio.com/listener for privacy information.

“The most effective therapies for solid tumors are also the most toxic — and we need to fix that,” says Dr. John Connolly, chief scientific officer of the Parker Institute for Cancer Immunotherapy. In this episode of the Vanguards of Health Care podcast, Connolly tells Bloomberg Intelligence pharmaceutical analyst Sam Fazeli why managing toxicity is the key to unlocking CAR-T’s potential in solid tumors. They explore the rise of in vivo cell therapies, evolving views on the tumor microenvironment and why foundational cancer vaccines may shape the future of all immunotherapy. Connolly also shares the clinical trials he’s watching closely, the ones that could flip the script on cancer care.See omnystudio.com/listener for privacy information.

On this episode of the Astonishing Healthcare podcast, Bloomberg Intelligence's Jonathan Palmer (Sr. Equity Analyst & Team Lead, Healthcare) joins us in the studio for a discussion about the work his team does and the evolving landscape of health tech. Palmer notes interest in Hinge Health's potential IPO and how the market's receptivity to tech-enabled healthcare companies has improved recently. While these companies face pressure to demonstrate profitability amid evolving market dynamics, there's optimism about innovation on several fronts. He also explains the impact of health policy uncertainty and questions about what the FDA, FTC, DOJ, and CMS will do on investors' ability to place bets: ambiguity causes market hesitation, and investors gravitate toward safe havens.The discussion also covers areas of focus for 2025, including:Palmer's favorite Vanguards of Healthcare podcast episodes and why he enjoys speaking with private company CEOs and venture capital leadersBiopharma Innovation, including GLP-1s, oncology readoutsMedTech Advancements like surgical robotics, cardioablation, and evolving insulin delivery systemsCapital Spending Concerns as US providers and China's healthcare sector are under scrutinyHealthcare Services: online pharmacy growth and Medicare Advantage trendsReference Materials Courtesy of Bloomberg IntelligenceNorth America Managed-Care Policy OutlookN.A. Health-Care Tech, Distribution: 2025 OutlookRelated ContentVanguards of Health Care: How Capital Rx is Fixing America's Broken Drug PricingAH057 - How First-Movers are Taking Control of their Health Plans in 2025, with Jeff HoganAH047 - What Project 2025, RFK Jr., and Dr. Oz Could Mean for the Business of Healthcare Under TrumpAH046 - What's Hot In and Around the Pharmacy Supply Chain, with RSM's Tom EveganFor more information about Capital Rx and this episode, please visit Capital Rx Insights.

Cardiac monitoring “is a space that hasn’t seen disruption or innovation for 50 to 60 years, and we’re trying to disrupt that with our AI-powered Zio platform,” iRhythm CEO Quentin Blackford tells Bloomberg Intelligence. “And really, the focus is on how do we enable an earlier, more accurate diagnosis while reducing the workflow effects for our physicians?” In this episode of the Vanguards of Health Care podcast, Blackford sits down with BI analyst Matt Henriksson to talk about iRhythm, how its Zio-platform technology powered by its AI network allows patients to be monitored without disrupting their everyday lives, and how its clinical data could support a more proactive screening of patients to find arrhythmias before a catastrophic adverse event occurs.See omnystudio.com/listener for privacy information.

The crew delve more into vanguards, and discover that Colin belongs in a museum.

“We decided to come to the table with a health-plan model that enables what we like to call radical affordability,” said Ashok Subramanian, CEO and co-founder of Centivo, in this episode of the Vanguards of Health Care podcast. Subramanian joins Bloomberg Intelligence analyst Jonathan Palmer to discuss how Centivo’s approach to self-funded employer plans focuses on reducing costs without sacrificing quality. By leveraging direct-provider partnerships and emphasizing primary care, the company aims to keep 75% of members’ out-of-pocket costs below $200 per year. The conversation covers how Centivo differentiates itself from traditional insurers, its expansion into new markets, and how it helps employers navigate high-cost treatments like GLP-1 drugs while maintaining sustainable benefits for workers. See omnystudio.com/listener for privacy information.

JR has drummed on over 200 US Billboard Hot 100 songs and 50 Grammy winning tunes. He was in Rufus w/ Chaka Khan in the late 70s/early 80s, has released two solo albums, written for soundtracks, produced other artists, and has led various combos over the years. He is currently promoting his auto-biography King of the Groove. We discuss "Gonna Be Alright" from The Bronx, USA soundtrack (2020), "Flight 81" from his first solo album, Funkshui (2004), and "You're Really Out of Line" by Rufus from Seal in Red (1983). End song: "Tal Shia" by SRT from Vanguards of Groove (2023). Intro: "Higher Love" by Steve Winwood (1986). More at johnjrrobinson.com. Hear more Nakedly Examined Music. Support us on Patreon.

“As US biotech companies, how do we continue to differentiate and create novel breakthrough assets? I think it’s leveraging AI,” said Sean McClain, founder and CEO of Absci. McClain and Christian Stegmann, senior vice president of drug creation, sit down with Bloomberg Intelligence analyst Andrew Galler in this episode of the Vanguards of Health Care podcast to discuss Absci’s generative AI platform and developing best-in-class biologics.See omnystudio.com/listener for privacy information.

As Wall Street swooned and boomed through the last decade, our livelihoods have—now more than ever—come to rely upon the good sense and risk appetites of a few standout investors. And amidst the BlackRocks, Vanguards, and Berkshire Hathaways stands arguably the most iconoclastic of them all: SoftBank's Masayoshi Son. In Gambling Man: The Wild Ride of Japan's Masayoshi Son (Atria, 2024), the first Western biography of Son, the self-professed unicorn hunter, we go behind the scenes of the world's most monied halls of power in New York, Tokyo, Silicon Valley, Saudi Arabia, and beyond to see how Son's firm SoftBank has defied conventional wisdom and imposing odds to push global tech and commerce into the future. From the dizzying highs of Uber, DoorDash, and Slack to the epic lows of WeWork and tech-infused dogwalking app Wag Son and SoftBank have been at the center of cutting-edge capitalism's absolute peaks and valleys. In the process, Son, son of a pachinko kingpin who grew up in a slum in Japan, has been a hero, a villain, and even a meme-ified hero to the internet tech- and finance-bro set all at once. Based on in-depth research and eye-opening interviews, Gambling Man is an unforgettable character study and alarming true story of twenty-first-century commerce that will stick with you long after you turn the final page. Lionel Barber is the former editor of the Financial Times. As editor, he interviewed many of the world's leaders in business and politics, including US Presidents Barack Obama and Donald Trump, Russian President Vladimir Putin, Chancellor Angela Merkel of Germany, and Indian Prime Minister Narendra Modi. Barber has co-written several books and has lectured widely on foreign policy, transatlantic relations, and economics. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

As Wall Street swooned and boomed through the last decade, our livelihoods have—now more than ever—come to rely upon the good sense and risk appetites of a few standout investors. And amidst the BlackRocks, Vanguards, and Berkshire Hathaways stands arguably the most iconoclastic of them all: SoftBank's Masayoshi Son. In Gambling Man: The Wild Ride of Japan's Masayoshi Son (Atria, 2024), the first Western biography of Son, the self-professed unicorn hunter, we go behind the scenes of the world's most monied halls of power in New York, Tokyo, Silicon Valley, Saudi Arabia, and beyond to see how Son's firm SoftBank has defied conventional wisdom and imposing odds to push global tech and commerce into the future. From the dizzying highs of Uber, DoorDash, and Slack to the epic lows of WeWork and tech-infused dogwalking app Wag Son and SoftBank have been at the center of cutting-edge capitalism's absolute peaks and valleys. In the process, Son, son of a pachinko kingpin who grew up in a slum in Japan, has been a hero, a villain, and even a meme-ified hero to the internet tech- and finance-bro set all at once. Based on in-depth research and eye-opening interviews, Gambling Man is an unforgettable character study and alarming true story of twenty-first-century commerce that will stick with you long after you turn the final page. Lionel Barber is the former editor of the Financial Times. As editor, he interviewed many of the world's leaders in business and politics, including US Presidents Barack Obama and Donald Trump, Russian President Vladimir Putin, Chancellor Angela Merkel of Germany, and Indian Prime Minister Narendra Modi. Barber has co-written several books and has lectured widely on foreign policy, transatlantic relations, and economics. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history

As Wall Street swooned and boomed through the last decade, our livelihoods have—now more than ever—come to rely upon the good sense and risk appetites of a few standout investors. And amidst the BlackRocks, Vanguards, and Berkshire Hathaways stands arguably the most iconoclastic of them all: SoftBank's Masayoshi Son. In Gambling Man: The Wild Ride of Japan's Masayoshi Son (Atria, 2024), the first Western biography of Son, the self-professed unicorn hunter, we go behind the scenes of the world's most monied halls of power in New York, Tokyo, Silicon Valley, Saudi Arabia, and beyond to see how Son's firm SoftBank has defied conventional wisdom and imposing odds to push global tech and commerce into the future. From the dizzying highs of Uber, DoorDash, and Slack to the epic lows of WeWork and tech-infused dogwalking app Wag Son and SoftBank have been at the center of cutting-edge capitalism's absolute peaks and valleys. In the process, Son, son of a pachinko kingpin who grew up in a slum in Japan, has been a hero, a villain, and even a meme-ified hero to the internet tech- and finance-bro set all at once. Based on in-depth research and eye-opening interviews, Gambling Man is an unforgettable character study and alarming true story of twenty-first-century commerce that will stick with you long after you turn the final page. Lionel Barber is the former editor of the Financial Times. As editor, he interviewed many of the world's leaders in business and politics, including US Presidents Barack Obama and Donald Trump, Russian President Vladimir Putin, Chancellor Angela Merkel of Germany, and Indian Prime Minister Narendra Modi. Barber has co-written several books and has lectured widely on foreign policy, transatlantic relations, and economics. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/east-asian-studies

As Wall Street swooned and boomed through the last decade, our livelihoods have—now more than ever—come to rely upon the good sense and risk appetites of a few standout investors. And amidst the BlackRocks, Vanguards, and Berkshire Hathaways stands arguably the most iconoclastic of them all: SoftBank's Masayoshi Son. In Gambling Man: The Wild Ride of Japan's Masayoshi Son (Atria, 2024), the first Western biography of Son, the self-professed unicorn hunter, we go behind the scenes of the world's most monied halls of power in New York, Tokyo, Silicon Valley, Saudi Arabia, and beyond to see how Son's firm SoftBank has defied conventional wisdom and imposing odds to push global tech and commerce into the future. From the dizzying highs of Uber, DoorDash, and Slack to the epic lows of WeWork and tech-infused dogwalking app Wag Son and SoftBank have been at the center of cutting-edge capitalism's absolute peaks and valleys. In the process, Son, son of a pachinko kingpin who grew up in a slum in Japan, has been a hero, a villain, and even a meme-ified hero to the internet tech- and finance-bro set all at once. Based on in-depth research and eye-opening interviews, Gambling Man is an unforgettable character study and alarming true story of twenty-first-century commerce that will stick with you long after you turn the final page. Lionel Barber is the former editor of the Financial Times. As editor, he interviewed many of the world's leaders in business and politics, including US Presidents Barack Obama and Donald Trump, Russian President Vladimir Putin, Chancellor Angela Merkel of Germany, and Indian Prime Minister Narendra Modi. Barber has co-written several books and has lectured widely on foreign policy, transatlantic relations, and economics. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/biography

Episode 45 - Murdock and Marvel: 1997 Part 2 We've got a pretty quiet week in comic terms, partly because everything has gone completely to the dogs, and there is a lot less happening than there was a few years ago.  Still, I was surprised to find that 1997 had some pretty great things going on under the surface!  This is part 2 of the podcast. that will feature the year in Daredevil, the Spotlight story and the Takeaway for 1997.   The Year in Daredevil  Appearances: Daredevil #360-370, Daredevil #-1, Adventures of Spider-Man #10, Bug #1, Code of Honor #2-4, Punisher #17-18, Venom: On Trial #1-3, Marvel Valentine Special #1, Silver Surfer #128, Essential Spider-Man #2, Electra #-1, Ka-Zar #5 and 8, Uncanny Origins #13, Elektra #10-11 and 13, Marvel Heroes & Legends 1997 #1, Spider-Man El Hombre Arana #30, Spider-Man Unlimited #18, Thunderbolts #8 along with Daredevil/Batman, Untold Tales of Spider-Man '97, Kingpin, Origin of Marvel Comics Revised Edition and Son of Origins of the Marvel Comics Revised Edition graphic novels  Writing: Karl Kesel (#360-364), Joe Kelly (#365-370 and #-1)  Pencils: Cary Nord (#360-362, 364-365), Gene Colan (#363, -1, 366-368, 370), Ariel Olivetti (#369)  Inks: Matt Ryan (#360-362, 364-365, -1), Cam Smith and Paul Neary (#363), Al Williamson (#366), Bud LaRosa (#367-368, 370), Pier Brito (#369)  The year begins with Daredevil taking on the Absorbing Man as he tries to take down NYC with no Avengers to stop him. While that's going on, we learn why Foggy was so keen on partnering with Rosalind Sharpe – she's his biological mother.  And it's Sharpe who thinks Foggy and the firm need to play up Foggy's “best bud” status with Daredevil – which leads to work for the firm as Molten Man (Mark Raxton) seeks help with break-ins at Osborne Chemicals. Daredevil is reunited with the Black Widow as the pair take down the Grey Gargoyle.  We learn a bit about Rosalind's Sharpe's past after Daredevil saves her from an armed man in the firm's lobby then follow's her to visit the gangster responsible.   Next we get a multi-book story involving a new villainous, Insomnia – he's try to keep Daredevil and the rest of New York up at night. We eventually learn she's working for Mr Fear – who himself is causing trouble by enlisting a friend of Molten Man to release a gas during a Osborn Chemicals boardroom meeting which causes Raxton to freak out and start tearing the place apart.  Before we can get a resolution to Mr Fear, we get a Flashback issue of Daredevil (Daredevil #-1) in which Jack Murdock is taking his son Matt to college. This story, from writer Joe Kelly and art by Gene Colan and Matt Ryan is a lot of fun and will be our spotlight story of the week.  Returning back to present time, Daredevil must, once again, deal with Mr Fear's plotting – this time on Ryker's Island when Fear releases a gas to start a prison riot. Daredevil must then take on new and improved Gladiator. (what happened to fear???)  The year ends with a multi-book storyline called “widow's Kiss” that starts with Daredevil helping a firm client who's facing a hostile takeover by the Russians – only to have to tangle Omega Red. Black Widow comes to the aid of Daredevil only to then shoot him herself. She tries then save DD by bring him to Karen for help, before returning to meet with a Russian general we eventually learn she's trying to take down. Despite just being shot, Daredevil goes after Widow and gets the pair captured. The story ends Daredevil escapes and convinces Ursa Major and Vanguard that they are being used by the General – and that he's being running experiments on Vanguards sister – Darkstar.  One other secondary story that ran through much of the year involves Foggy and Liz Osborne. Rosalind Sharpe isn't pleased with their relationship and continually tries to undermine it – with other women. In the final book of the year Foggy and Liz's attempt to have a romantic evening together is derailed when he receives a constant stream of phone calls from other women.  This Week's Spotlight: Daredevil #-1 July 1997 “A Time to Say Farewell”  Recap Why We Picked This Story Daredevil Rapid Fire Questions The Takeaway Marvel messed up more than their own fortunes with their unwise expansions.  Questions or comments We'd love to hear from you!  Email us at questions@comicsovertime.com or find us on Twitter @comicsoftime. ------------------ THANKS TO THE FOLLOWING CREATORS AND RESOURCES  Music: Our theme music is by the very talented Lesfm.  You can find more about them and their music at https://pixabay.com/users/lesfm-22579021/.  The Grand Comics Database: Dan uses custom queries against a downloadable copy of the GCD to construct his publisher, title and creator charts.  Comichron: Our source for comic book sales data.  The American Comic Book Chronicles: Published by TwoMorrows, these volumes provide an excellent analysis of American comics through the years.  Because these volumes break down comic history by year and decade they are a great place to get a basic orientation on what is happening across the comic industry at a particular point in time. 

Today we talk more about the new Vanguard CEO and Ascensus acquiring Vanguards's individual 401(k) business. We answer a few questions about DAFs and if appreciated securities are a reasonable alternative to DAFs. We talk about donating real estate to charity and then get into detail about contributing to your non dependent adult child's HSA. Today's episode is brought to you by SoFi, helping medical professionals like us bank, borrow, and invest to achieve financial wellness. SoFi offers up to 4.6% APY on their savings accounts, as well as an investment platform, financial planning, and student loan refinancing…featuring an exclusive rate discount for med professionals and $100/month payments for residents. Check out all that SoFi offers at https://www.whitecoatinvestor.com/Sofi *Loans originated by SoFi Bank, N.A., NMLS 696891. Advisory services by SoFi Wealth LLC. The brokerage product is offered by SoFi Securities LLC, Member FINRA/SIPC. Investing comes with risk including risk of loss. Additional terms and conditions may apply. The White Coat Investor has been helping doctors with their money since 2011. Our free financial planning resource covers a variety of topics from doctor mortgage loans and refinancing medical school loans to physician disability insurance and malpractice insurance. Learn about loan refinancing or consolidation, explore new investment strategies, and discover loan programs specifically aimed at helping doctors. If you're a high-income professional and ready to get a "fair shake" on Wall Street, The White Coat Investor is for you! Main Website: https://www.whitecoatinvestor.com  YouTube: https://www.whitecoatinvestor.com/youtube  Student Loan Advice: https://studentloanadvice.com  Facebook: https://www.facebook.com/thewhitecoatinvestor  Twitter: https://twitter.com/WCInvestor  Instagram: https://www.instagram.com/thewhitecoatinvestor  Subreddit: https://www.reddit.com/r/whitecoatinvestor  Online Courses: https://whitecoatinvestor.teachable.com  Newsletter: https://www.whitecoatinvestor.com/free-monthly-newsletter